Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Legend Biotech Corporation, Axsome Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Legend Biotech Corporation, Axsome Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Legend Biotech Corporation, Axsome Therapeutics and Inc.

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Latest Biotechnology and Legend Biotech Corporation, Axsome Therapeutics, Inc. Stock News

As of September 2, 2026, Legend Biotech Corporation had a $4.2 billion market capitalization, compared to the Biotechnology median of $288.9 million. Legend Biotech Corporation’s stock is in 2026, up 6.1% in the previous five trading days and down 36.03% in the past year.

Currently, Legend Biotech Corporation does not have a price-earnings ratio. Legend Biotech Corporation’s trailing 12-month revenue is $1.3 billion with a -7.2% net profit margin. Year-over-year quarterly sales growth most recently was 51.9%. Analysts expect adjusted earnings to reach $-0.010 per share for the current fiscal year. Legend Biotech Corporation does not currently pay a dividend.

As of September 2, 2026, Axsome Therapeutics, Inc. had a $11.0 billion market cap, putting it in the 79th percentile of all stocks. Axsome Therapeutics, Inc.’s stock is up 14.1% in 2026, up 1% in the previous five trading days and up 70.02% in the past year.

Currently, Axsome Therapeutics, Inc. does not have a price-earnings ratio. Axsome Therapeutics, Inc.’s trailing 12-month revenue is $776.6 million with a -24.7% net profit margin. Year-over-year quarterly sales growth most recently was 45.6%. Analysts expect adjusted earnings to reach $-2.637 per share for the current fiscal year. Axsome Therapeutics, Inc. does not currently pay a dividend.

How We Compare Legend Biotech Corporation, Axsome Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Legend Biotech Corporation, Axsome Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Legend Biotech Corporation, Axsome Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Legend Biotech Corporation	LEGN	D
Axsome Therapeutics, Inc.	AXSM	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Legend Biotech Corporation has a Value Score of 25, which is Expensive. Axsome Therapeutics, Inc. has a Value Score of 3, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Legend Biotech Corporation, Axsome Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Legend Biotech Corporation, Axsome Therapeutics or Inc. is the better investment when it comes to value.

Legend Biotech Corporation, Axsome Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Legend Biotech Corporation	LEGN	F
Axsome Therapeutics, Inc.	AXSM	na

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Legend Biotech Corporation has a Growth Score of 18, which is Very Weak. Axsome Therapeutics, Inc. does not have a meaningful Growth Score.

The Growth Stock Winner: No Clear Winner

Neither Legend Biotech Corporation, Axsome Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Legend Biotech Corporation, Axsome Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Legend Biotech Corporation, Axsome Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Legend Biotech Corporation	LEGN	F
Axsome Therapeutics, Inc.	AXSM	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Legend Biotech Corporation has a Earnings Estimate Score of 3, which is Very Negative. Axsome Therapeutics, Inc. has a Earnings Estimate Score of 12, which is Very Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Legend Biotech Corporation, Axsome Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Legend Biotech Corporation, Axsome Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Legend Biotech Corporation, Axsome Therapeutics and Inc. Grades

In addition to Growth, Value and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Legend Biotech Corporation, Axsome Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Legend Biotech Corporation, Axsome Therapeutics or Inc. Stock?

Overall, Legend Biotech Corporation stock has a Value Score of 25, Growth Score of 18 and Estimate Revisions Score of 3.

Axsome Therapeutics, Inc. stock has a Value Score of 3, Growth Score of and Estimate Revisions Score of 12.

Comparing Legend Biotech Corporation, Axsome Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.